Measurement of antibody responses to Modified Vaccinia virus Ankara (MVA) and Dryvax® using proteome microarrays and development of recombinant protein ELISAs

Ítems similars

• Antibody Profiling by Proteome Microarray Reveals the Immunogenicity of the Attenuated Smallpox Vaccine Modified Vaccinia Virus Ankara Is Comparable to That of Dryvax
  per: Davies, D. Huw, et al.
  Publicat: (2008)
• Safety, Immunogenicity and Efficacy of Modified Vaccinia Ankara (MVA) Against Dryvax(®) Challenge in Vaccinia-Naïve and Vaccinia-Immune Individuals
  per: Parrino, Janie, et al.
  Publicat: (2006)
• T cell antigen discovery using soluble vaccinia proteome reveals recognition of antigens with both virion and non-virion association
  per: Davies, D. Huw, et al.
  Publicat: (2014)
• Failure of the Smallpox Vaccine To Develop a Skin Lesion in Vaccinia Virus-Naïve Individuals Is Related to Differences in Antibody Profiles before Vaccination, Not After
  per: Tan, Xiaolin, et al.
  Publicat: (2012)
• Effect of Immunization with Modified Vaccinia Ankara (ACAM3000) on Subsequent Challenge with Dryvax
  per: Seaman, Michael S., et al.
  Publicat: (2010)